Taipei Exchange - Delayed Quote TWD

Mycenax Biotech Inc. (4726.TWO)

39.40
-0.90
(-2.23%)
At close: 1:30:18 PM GMT+8
Currency in TWD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
725,450
683,924
652,620
732,276
774,270
Cost of Revenue
958,607
925,281
1,027,811
845,948
636,661
Gross Profit
-233,157
-241,357
-375,191
-113,672
137,609
Operating Expense
219,802
220,126
228,042
300,165
230,097
Operating Income
-452,959
-461,483
-603,233
-413,837
-92,488
Net Non Operating Interest Income Expense
-24,246
-21,393
-9,585
-15,399
-2,223
Pretax Income
-466,641
-469,586
-683,981
-462,841
-87,518
Tax Provision
-5,990
-2,461
-1,134
-9,210
2,340
Net Income Common Stockholders
-460,651
-467,125
-682,847
-453,631
-89,858
Diluted NI Available to Com Stockholders
-460,651
-467,125
-682,847
-453,631
-89,858
Basic EPS
-2.23
-2.27
-3.32
-2.74
-0.61
Diluted EPS
-2.23
-2.27
-3.32
-2.74
-0.61
Basic Average Shares
206,702.57
205,999
205,528
165,337
148,484
Diluted Average Shares
206,702.57
205,999
205,528
165,337
148,484
Total Expenses
1,178,409
1,145,407
1,255,853
1,146,113
866,758
Net Income from Continuing & Discontinued Operation
-460,651
-467,125
-682,847
-453,631
-89,858
Normalized Income
-459,696.41
-467,071.28
-683,976.12
-423,093.01
-95,583.60
Interest Income
7,313
8,524
17,660
3,795
307
Interest Expense
31,559
29,917
27,245
19,194
2,530
Net Interest Income
-24,246
-21,393
-9,585
-15,399
-2,223
EBIT
-435,082
-439,669
-656,736
-443,647
-84,988
EBITDA
-136,319
-136,455
-341,955
-161,094
82,833
Reconciled Cost of Revenue
958,607
925,281
1,027,811
845,948
636,661
Reconciled Depreciation
298,763
303,214
314,781
282,553
167,821
Net Income from Continuing Operation Net Minority Interest
-460,651
-467,125
-682,847
-453,631
-89,858
Total Unusual Items Excluding Goodwill
-967
-54
1,131
-31,158
7,157
Total Unusual Items
-967
-54
1,131
-31,158
7,157
Normalized EBITDA
-135,352
-136,401
-343,086
-129,936
75,676
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-12.41
-0.28
1.88
-620.01
1,431.40
12/31/2021 - 6/20/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6535.TWO Lumosa Therapeutics Co., Ltd.
176.50
+1.15%
 
6589.TWO EirGenix Inc.
63.10
-0.94%
 
6733.TWO BioGend Therapeutics Co., Ltd.
31.15
+0.48%
 
4168.TWO GlycoNex Incorporation
25.05
-3.65%
 
3205.TWO Sagittarius Life Science Corp
43.95
+4.02%
 
4174.TWO OBI Pharma, Inc.
35.35
+2.17%
 
4167.TWO Savior Lifetec Corporation
21.60
+0.93%
 
6838.TW Formosa Pharmaceuticals, Inc.
34.15
+9.98%
 
6550.TW Polaris Group
40.00
+0.25%
 
4147.TWO TaiMed Biologics Inc.
82.70
+1.10%